20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Century Therapeutics Inc (IPSC) operates in the BIOTECHNOLOGY industry and is headquartered in Philadelphia, United States with about 78 employees. Its market capitalization is roughly $266 million. In the fiscal year ended 2025-12-31, IPSC reported $109M in revenue and ($10M) in net income.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $109M | $7M | $2M | $5M | $1M | $0M | $0M | $470M | $951M |
| Gross Profit | — | $96M | $7M | $2M | $5M | ($5M) | ($2M) | $0M | $2M | $62M |
| Gross Margin % | — | 88.0% | 100.0% | 100.0% | 100.0% | -433.1% | — | — | 0.5% | 6.5% |
| Operating Income (EBIT) | ($120M) | ($15M) | ($138M) | ($147M) | ($134M) | ($95M) | ($49M) | ($20M) | — | — |
| Operating Margin % | — | -13.8% | -2096.5% | -6556.9% | -2574.2% | -8968.1% | — | — | — | — |
| Net Income | ($110M) | ($10M) | ($127M) | ($137M) | ($131M) | ($96M) | ($54M) | ($245M) | — | — |
| Net Margin % | — | -8.8% | -1920.9% | -6115.1% | -2518.4% | -9057.1% | — | — | — | — |
| EBITDA | ($96M) | $3M | ($111M) | ($121M) | ($121M) | ($90M) | ($51M) | ($245M) | — | — |
| Earnings Per Share (EPS) | $-1.04 | $-0.11 | $-1.61 | $-2.30 | $-2.27 | $-1.74 | $-0.98 | $-4.46 | — | — |
| Shares Outstanding (M) | 206M | 87M | 79M | 59M | 58M | 55M | 55M | 55M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $109M | $4M | $1M |
| Gross Profit | — | ($3M) | ($4M) | ($23M) | ($27M) | $109M | $4M | $1M |
| Gross Margin % | — | — | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($37M) | ($26M) | ($21M) | ($36M) | ($35M) | $74M | ($37M) | ($35M) |
| Operating Margin % | — | — | — | — | — | 68.0% | -893.5% | -4398.1% |
| Net Income | ($35M) | ($22M) | ($19M) | ($34M) | ($33M) | $77M | ($36M) | ($31M) |
| Net Margin % | — | — | — | — | — | 70.1% | -864.4% | -3947.7% |
| EBITDA | ($35M) | ($19M) | ($16M) | ($26M) | ($29M) | $80M | ($31M) | ($28M) |
| Earnings Per Share (EPS) | $-0.17 | $-0.25 | $-0.22 | $-0.40 | $-0.38 | $0.89 | $-0.46 | $-0.37 |
| Shares Outstanding (M) | 206M | 87M | 87M | 86M | 86M | 86M | 79M | 85M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($87M) | ($104M) | ($110M) | ($88M) | $14M | ($89M) | ($41M) | ($16M) | — | $104M |
| Capital Expenditures (CapEx) | $2M | $1M | $0M | $14M | $31M | $45M | $10M | $2M | $11M | $29M |
| Free Cash Flow (FCF) | ($89M) | ($105M) | ($110M) | ($102M) | ($17M) | ($134M) | ($51M) | ($19M) | — | $75M |
| FCF Margin % | — | -95.9% | -1673.8% | -4567.5% | -318.4% | -12662.8% | — | — | — | 7.9% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($20M) | ($25M) | ($16M) | ($26M) | ($28M) | ($35M) | ($24M) | ($28M) |
| Capital Expenditures (CapEx) | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $1M |
| Free Cash Flow (FCF) | ($21M) | ($26M) | ($16M) | ($26M) | ($28M) | ($35M) | ($24M) | ($29M) |
| FCF Margin % | — | — | — | — | — | -32.1% | -584.2% | -3686.1% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $287M | $224M | $353M | $361M | $487M | $437M | $107M | $91M | $758M | $845M |
| Cash & Cash Equivalents | $50M | $62M | $58M | $47M | $84M | $56M | $27M | $44M | $21M | $0M |
| Total Liabilities | $55M | $65M | $192M | $176M | $184M | $41M | $213M | $183M | $576M | $485M |
| Total Debt (Short + Long-Term) | $0M | $3M | $5M | $2M | $11M | $11M | $10M | $0M | $275M | $156M |
| Total Shareholders' Equity | $232M | $159M | $161M | $185M | $303M | $396M | ($106M) | ($92M) | $182M | $360M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IPSC viewer.
About TickerBase · Data methodology & sources · Privacy · Terms